uniQure (NASDAQ:QURE) Price Target Cut to $16.00 by Analysts at Chardan Capital

uniQure (NASDAQ:QURE) had its price objective trimmed by Chardan Capital from $53.00 to $16.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also commented on QURE. Cantor Fitzgerald reiterated a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research report on Monday. Benchmark reiterated a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Stifel Nicolaus set a $14.00 target price on uniQure in a research report on Monday. The Goldman Sachs Group lowered their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Finally, TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $34.33.

uniQure Trading Down 14.0%

QURE stock opened at $9.03 on Tuesday. The firm has a fifty day moving average price of $22.86 and a 200 day moving average price of $29.72. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The firm has a market cap of $562.48 million, a PE ratio of -2.62 and a beta of 0.73. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 230.98%. The company had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. Sell-side analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other uniQure news, CFO Christian Klemt sold 6,217 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $148,337.62. Following the sale, the chief financial officer owned 211,513 shares in the company, valued at $5,046,700.18. This trade represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the sale, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 50,598 shares of company stock worth $1,248,588. Insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently modified their holdings of the stock. Private Trust Co. NA purchased a new stake in shares of uniQure in the third quarter valued at approximately $28,000. Torren Management LLC bought a new stake in uniQure during the 4th quarter valued at $28,000. Jones Financial Companies Lllp lifted its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. IFP Advisors Inc bought a new position in shares of uniQure during the 4th quarter worth $48,000. Finally, Smartleaf Asset Management LLC bought a new position in shares of uniQure during the 4th quarter worth $48,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat the EPS consensus (reported loss narrower than expected) and revenue slightly exceeded estimates — provides near‑term financial relief but did not offset regulatory concerns. Q4 press release
• Positive Sentiment: Some analysts remain constructive after repricing: Chardan retained a “buy” rating (lowered PT) and Wells Fargo kept an “equal weight” stance, which could support buyer interest if worries ease. Analyst notes
• Neutral Sentiment: uniQure says it held a Type A meeting with the FDA, is evaluating Phase‑III plans for AMT‑130 and intends to request a follow‑up Type B meeting in Q2 — this signals a defined regulatory path but will likely take time and resources. Company update
• Neutral Sentiment: Corporate disclosure flagged a governance risk tied to a 2026 shift to the Dutch “large company” regime — a longer‑term structural governance change that bears monitoring but is not an immediate earnings driver. TipRanks note
• Negative Sentiment: Regulatory blow: the FDA told uniQure its early‑stage AMT‑130 data are insufficient for a marketing application and has recommended a randomized, sham‑controlled Phase III study — a materially more onerous and time‑consuming path that triggered the sharp market selloff. Reuters: FDA tells UniQure
• Negative Sentiment: Analysts slashed price targets and ratings after the FDA decision (Goldman lowered its PT to $9 and moved to neutral; Cantor, RBC, Mizuho and others also cut PTs or ratings) — analyst repricing removes supporting buy‑side momentum and amplifies downside risk. Analyst coverage changes
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for securities class actions tied to the company’s disclosures during a defined class period — increased legal risk, potential settlements or litigation costs add uncertainty for shareholders. Rosen Law Firm notice
• Negative Sentiment: Market reaction: heavy volume and steep price declines since the FDA announcement reflect rapid repricing of AMT‑130’s value and higher execution risk for the company’s lead gene‑therapy program. Bloomberg coverage

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.